

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

What is claimed is:

1. (Currently Amended) A method of treating ~~and/or preventing~~ a vascular disease characterized by nitric oxide insufficiency in a patient in need thereof comprising administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, ~~nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated angiotensin II receptor antagonist, nitrosated endothelin antagonist, nitrosated renin inhibitor, or a mixture of two or more thereof.~~ wherein the nitrosated angiotensin-converting enzyme inhibitor is a nitrosated alacepril, a nitrosated benazepril, a nitrosated captopril, a nitrosated ceronapril, a nitrosated cilazapril, a nitrosated delapril, a nitrosated duinapril, a nitrosated enalapril, a nitrosated enalaprilat, a nitrosated fosinopril, a nitrosated imidapril, a nitrosated lisinopril, a nitrosated moveltipril, a nitrosated naphthopidil, a nitrosated pentopril, a nitrosated perindopril, a nitrosated quinapril, a nitrosated ramipril, a nitrosated rentipril, a nitrosated spirapril, a nitrosated temocapril, a nitrosatedtrandolapril, a nitrosated urapidil or a nitrosated zofenopril.

2. (Original) The method of claim 1, further comprising administering a pharmaceutically acceptable carrier.

3. (Original) The method of claim 1, wherein the vascular disease characterized by nitric oxide insufficiency is a cardiovascular disease; a disease resulting from oxidative stress; low-renin hypertension; salt-sensitive hypertension; low-renin, salt-sensitive hypertension; primary pulmonary hypertension; thromboembolic pulmonary hypertension; pregnancy-induced hypertension; renovascular hypertension; hypertension-dependent end-stage renal disease; heart failure; microvascular cardiac ischemia; left ventricular hypertrophy with disproportionate microvascularization or diastolic dysfunction.

4. (Original) The method of claim 3, wherein the cardiovascular disease is congestive heart failure, hypertension, pulmonary hypertension, myocardial infarction, cerebral infarction, atherosclerosis, atherogenesis, thrombosis, ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal failure, stable, unstable or variant (Prinzmetal) angina, cardiac

edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attack, cerebrovascular accident, restenosis, controlling blood pressure in hypertension, platelet adhesion, platelet aggregation, smooth muscle cell proliferation, vascular complication associated with the use of medical device, wound associated with the use of medical device, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, thrombocytopenia or bleeding disorder.

5. (Original) The method of claim 4, wherein the cardiovascular disease is congestive heart failure, hypertension, restenosis or atherosclerosis.

6. (Original) The method of claim 3, wherein the disease resulting from oxidative stress is atherogenesis, atheromatosis, arteriosclerosis, atherosclerosis, vascular hypertrophy associated with hypertension, hyperlipoproteinaemia, normal vascular degeneration through aging, parathyroidal reactive hyperplasia, chronic renal disease, a neoplastic disease, an inflammatory disease, a neurological and acute bronchopulmonary disease, tumorigenesis, ischemia-reperfusion syndrome, arthritis or sepsis.

7. (Currently Amended) The method of claim 1, wherein the at least one nitrosated angiotensin-converting enzyme inhibitor, ~~nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated angiotensin II receptor antagonist, nitrosated endothelin antagonist, nitrosated renin inhibitor, or mixture of two or more thereof~~ is in the form of a pharmaceutically acceptable salt.

8. (Currently Amended) The method of claim 1, wherein the at least one nitrosated angiotensin-converting enzyme inhibitor, ~~nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated angiotensin II receptor antagonist, nitrosated endothelin antagonist, nitrosated renin inhibitor, or mixture of two or more thereof~~, are orally administered as a solid dose.

9. (Original) The method of claim 8, wherein the solid dose is a tablet or a capsule.

10. (Original) The method of claim 9, wherein the tablet is a sustained release tablet or the capsule is a sustained release capsule.

11 – 20 (Cancelled)

21. (Original) The method of claim 1, further comprising administering to the patient a therapeutically effective amount of at least one compound used to treat a cardiovascular disease or a pharmaceutically acceptable salt thereof.

22. (Original) The method of claim 21, wherein the compound used to treat the cardiovascular disease is an angiotensin-converting enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel blocker, an angiotensin II receptor antagonist, an endothelin antagonist, a renin inhibitor, or a mixture of two or more thereof.

23-37 (Cancelled)